Novartis-partnered biotech nabs new cash, boosting efforts to develop 'functional cure' for chronic hepatitis B

Aayushi Pratap

News Reporter

Every year, 820,000 people die of chronic hepatitis B infections globally, and 1.5 million get infected, despite the availability of vaccines and treatments, according to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis-partnered biotech nabs new cash, boosting efforts to develop 'functional cure' for chronic hepatitis B

Aayushi Pratap

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

No­var­tis-part­nered biotech nabs new cash, boost­ing ef­forts to de­vel­op 'func­tion­al cure' for chron­ic he­pati­tis B

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novartis-partnered biotech nabs new cash, boosting efforts to develop 'functional cure' for chronic hepatitis B